Artivion | CRY

Stock Price
24.14
Daily Change
1.01 4.37%
Monthly
12.54%
Yearly
-23.34%
Q3 Forecast
23.59



Peers Price Chg Day Year Date
Terumo 2,179.50 -53.50 -2.40% -10.57% Jul/15
Abbott 88.86 -0.10 -0.11% -32.55% Jul/15
AngioDynamics 14.40 1.40 10.77% 67.44% Jul/15
Accuray 0.28 0.01 5.11% -79.44% Jul/15
AtriCure 34.99 0.67 1.95% 15.17% Jul/15
Baxter International 22.39 0.59 2.68% -21.10% Jul/15
Becton, Dickinson and Co. 155.60 4.95 3.29% -12.72% Jul/15
Boston Scientific 43.45 0.82 1.92% -57.89% Jul/15
Artivion 24.14 1.01 4.37% -23.34% Jul/15
Edwards Lifesciences 88.12 -1.97 -2.19% 15.73% Jul/15

Indexes Price Day Year Date
US2000 2974 8.57 0.29% 33.56% Jul/15

Artivion Inc traded at $23.83 this Wednesday July 15th, increasing $0.70 or 3.03 percent since the previous trading session. Looking back, over the last four weeks, Artivion gained 11.10 percent. Over the last 12 months, its price fell by 24.33 percent. Looking ahead, we forecast Artivion Inc to be priced at 23.59 by the end of this quarter and at 22.14 in one year, according to Trading Economics global macro models projections and analysts expectations.

CryoLife, Inc. (CryoLife), is a medical device company. The Company is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as Surgical Sealants, BioGlue products, JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PhotoFix, and NEXUS. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues.